We recently published a list of Jim Cramer Reveals Trump’s Potential Secret Weapon In China Trade Talks & Discusses These 10 ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...